Source
From SEC EDGAR
106 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Oral, highly selective and potent VAV1 molecular glue degrader designed to deliver a differentiated clinical profile across a broad range of…
LeMaitre Q3 2026 Financial Results
Dutch Bros Inc. Reports Third Quarter 2026 Financial Results
Achieves 30% Revenue Growth Year-Over-Year
Motorola Solutions Reports Third-Quarter 2026 Financial Results
Company raises full-year revenue and earnings outlook again and increases full-year cash flow expectations
Mativ Announces Third Quarter 2026 Results
ZoomInfo Announces Third Quarter 2026 Financial Results
Corpay Reports Third Quarter Financial Results
18% revenue growth, 11% organic revenue growth, and 32% adjusted EPS growth1
Klaviyo Delivers Solid Q3 with Enterprise Growth, Multi-Product Strength, and Agent Traction
Third quarter revenue of $387.2 million, representing 25% year-over-year growth
Fastly Announces Third Quarter 2026 Financial Results
Record third quarter revenue of $190.2 million grew 20% year-over-year
BBSI Reports Third Quarter 2026 Financial Results
- Revenues up 5% to $334.1 Million and Gross Billings up 3% to $2.40 Billion -
ParkOhio Announces Record Sales and Strong Third Quarter 2026 Results;
Raises FY 2026 Sales and Adjusted EPS Outlook on Continued Strong Demand Across Its Diversified End Markets
Dave Reports Third Quarter 2026 Financial Results
Q3 Revenue Growth Accelerates to 31% Y/Y to $198 Million, Driven by Record New Member Acquisition as well as Continued MTM Growth and ARPU Expansion